Antibody Fragments Market

Antibody Fragments Market Outlook (2022-2032)

The antibody fragments market is currently valued at USD 7.56 billion and is expected to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period. The market is to reach USD 13.41 Billion by 2032.

The increasing number of cancer cases around the world contributes to the antibody fragments market growth, which will eventually replace the full-length antibody. These are smaller and more easily penetrated, making them useful in the treatment of diseases like cancer, tumors, and COVID-19.

The growing geriatric population in developing economies such as India, Japan, Mexico, and China will boost demand for antibody fragments in the coming years. As second and third-generation technologies mature, demand for first-generation will decline. The COVID-19 pandemic boosted antibody fragments market demand because these are used in its treatment. With more diseases, the industry will continue to grow.

One of the key factors of the market is limiting the efficacy of antibody-targeted cancer therapies could be partial tumor penetration of the antibody-drug conjugate.

Report Attributes	Details
Market Size (2022)	USD 7.56 billion
Projected Market Value (2032)	USD 13.41 Billion
Global Market Growth Rate	5.9%
North America Market Share	50.0%
Japan Market Growth Rate	18.3%
Monoclonal Antibodies Market Share	95%
FAB Market Share	85%
Key Companies Profiled	Novartis AG F. Hoffmann-La Roche Ltd. Johnson & Johnson Services, Inc. Amgen Inc. Bristol-Myers Squibb Company AbbVie Inc. Takeda Pharmaceutical Company Limited Sanofi Biogen Inc. and Eli Lilly and Co.

Infectious and Chronic Diseases are Becoming Pervasive

Chronic conditions have been steadily increasing around the world as a result of an ageing population and societal behaviour changes.

The rapid growth of the middle class is causing people to adopt a more sedentary and unhealthy lifestyle, which is causing an increase in diseases such as diabetes. Due to the rapid population growth, the emerging antibody fragments market is expected to bear the greatest patient burden.

Antibody Fragments Preferred Over Alternatives

With rising rates of cancer, infectious diseases, and, as a result, immune deficiencies, there will be greater demand for antibody fragments. Globally, there has been an increase in the geriatric population. When it comes to the application prospects of antibody fragments, the market is expected to boom. Antibody fragments are also expected to be preferred over full-chain antibodies due to lower manufacturing and purification costs.

Strict ICD-10 guidelines may limit the use of certain antibody fragments in the treatment of a specific disease. New developments in the clinical development of antibody fragments for some of the deadliest diseases can give a massive opportunity for the antibody fragments market over the forecast period.

What Factors are Limiting Demand for Contract Manufacturing of Antibodies?

Global regulatory policies, cGMP, tightening inspection regimes, supply chain security issues across emerging markets, and R&D funding for some projects all have a significant impact on final product costs. Due to these factors, new entrants interested in biopharmaceutical contract manufacturing face financial challenges in the market for antibody fragments.

One of the major constraints is the high investment required for antibody fragments. Much of it has gone to tax havens like Ireland and Singapore, as well as emerging markets. Many businesses have reported a significant skills gap between qualified professionals and the current workforce. Many governments want to encourage the development of a mainstream biotech industry similar to the one in the United States, but progress has been slow. In most emerging countries, the growth of the antibody fragments industry has been hampered by insufficient funding, poor planning, and a scarcity of experienced individuals.

Segmentation Insights

Monoclonal Antibodies to Lead

The monoclonal antibodies segment had the highest revenue share of more than 95.0%. Monoclonal antibodies (mAbs) are a significant class of therapeutic agents used in the treatment of various types of cancer. However, the use of conventional mAbs in anticancer immunotherapies may encounter a number of limitations, including adverse effects and insufficient efficacy.

The use of antibody fragments in cancer therapy has received more attention than any other therapeutic application. However, its use in the development of pharmacological tools for the treatment of autoimmune diseases and infectious diseases is rapidly increasing.

Polyclonal antibodies (pAbs) have higher specificity and flexibility than monoclonal antibodies and are, therefore, superior for clinical applications. Researchers have had difficulty using pAbs antibody reagents because they are inconsistent in nature and interfere with their research studies. These are some of the factors that may limit the use of polyclonal antibodies, thereby limiting the market's overall growth.

FAB to Capture the Highest Market share

As the first generation of antibody fragments, the FAB segment captured the highest revenue share of more than 85.0% in 2021. Due to the rising prevalence of cancer, infectious diseases, and autoimmune diseases, there is a high demand for F(ab) fragments, which is fueling segment growth.

The approval and commercialization of novel therapies to aid in the treatment of life-threatening diseases are expected to drive segment growth. However, as molecule quality improves, market share is expected to decline over time with the introduction of second and third-generation molecules of antibody fragments.

Single-chain variable fragments (scFvs) are expected to grow at the fastest rate during the forecast period. They have several advantages over mAbs, including heterologous production, multivalency, low molecular weight, and multimeric form.

It is used in a variety of medical applications, such as bioimaging and targeted therapy. The scFv phage display antibody technology has quickly become one of the most popular ways to create recombinant antibodies. These factors are influencing segment growth.

Insights into Therapy Segment

The Ranibizumab segment had the highest revenue share. Ranibizumab is a monoclonal antibody fragment produced by recombinant DNA technology in E.coli cells.

In the pharmaceutical industry, it is available as an injection and is used to treat visual impairment caused by diabetic macular edoema, neovascular (wet) age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and other conditions.

Several academies and companies are working to understand the challenges and opportunities that could influence Ranibizumab research and development. Beovu (brolucizumab-dbll) is expected to grow the fastest during the forecast period. It is a monoclonal single-chain Fv antibody fragment used for intravitreal injection in the eye.

Insights into Application Segment

Due to the increasing prevalence of the disease globally, the immunodeficiency segment held the largest revenue share of more than 85.0% in 2021. Increased collaborations and partnerships for the development of novel therapies for immunocompromised patients are expected to support segment growth.

During the forecast period, the cancer segment is expected to grow the fastest. The high global prevalence of cancer is one of the major factors driving market growth over the forecast period. A high cancer incidence is expected to drive the adoption of novel and effective cancer diagnostic and therapeutic methods.

The other segment, which includes chronic diseases like age-related macular degeneration (AMD) and infectious diseases like HIV/AIDS and influenza, is expected to grow significantly in the coming years. Furthermore, key market participants are working on antibody fragments for eye disorders that are in the preclinical and clinical development stages.

Country Insights

North America Insights

North America dominated the antibody fragments market with a revenue share of more than 50.0%, owing to the expansion of regional pharmaceutical industries, which resulted in rising demand for antibody fragments. The rising prevalence of immunodeficiency diseases and cancer has increased the demand for antibody fragments for research purposes.

• What makes the United States the largest market for contract manufacturing of antibodies?

The United States dominates the North American region, with a total market share of 89.5%, and is expected to grow rapidly throughout the forecast period.

Rising R&D activities, the presence of leading market players, an established healthcare system, an increase in clinical trial numbers, and increased government interest in biologics are driving demand for antibody fragments.

Asia Pacific Insights

The developing antibody fragments market in Asia Pacific is expected to drive significant growth over the forecast period. Due to the increased emphasis on the biologics manufacturing sector, India and China are expected to dominate the market for antibody fragments.

• What makes Japan an emerging market for contract manufacturing of antibodies?

Japan is expected to hold an 8.9% share of the East Asian market, with a CAGR of around 18.3%. Advanced healthcare infrastructure, a growing interest in overseas expansion by Asian CDMOs, and massive-scale up capacities and capabilities are major factors contributing to the country's antibody fragments market growth.

• Why is India a growing market for contract manufacturing of antibodies?

With a 30% market share, India to dominate the South Asian market for antibody fragments.

The low labour cost, abundant raw material supply, significant manufacturing expertise, expanding advanced R&D facilities, and presence of major international and domestic players are driving demand for antibody fragments.

Europe Insights

• Why is the United Kingdom a profitable market for contract manufacturing of antibodies in Europe?

With a 26.8% share in 2021, the United Kingdom dominates the European market for antibody fragments.

The increasing demand for antibody-based therapeutics, the favourable safety profile of antibodies related to therapeutics, increased production capabilities, and the presence of prominent players are driving demand for antibody fragments.

Comparative View of Adjacent Antibody Fragments Market 

Antibody Fragments Market:

Attributes	Antibody Fragments Market
CAGR	5.9%
Market Value (2027)	USD 10.07 Billion
Growth Factor	Infectious and chronic diseases are becoming more common.
Opportunity	The growing geriatric population in developing economies will boost industrial demand in the coming years.
Key Trends	Antibody Fragments Preferentially Over Alternatives

Antibody Production Market:

Attributes	Antibody Production Market
CAGR	13.5%
Market Value (2027)	USD 29.80 Billion
Growth Factor	A major factor driving growth is the increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics.
Opportunity	A focus on R&D is an essential strategy for driving the company's long-term growth.
Key Trends	The production of therapeutic antibodies is increasing, which will drive market growth during the forecast period.

Research Antibodies Market:

Attributes	Research Antibodies Market
CAGR	4.93%
Market Value (2027)	USD 1.88 Billion
Growth Factor	The increased demand for high-quality antibodies for reproducible research is one of the key factors driving market growth.
Opportunity	The rising demand for protein therapies and personalised medicines is creating new market opportunities and promising lucrative growth for market participants.
Key Trends	The market is expanding as a result of the expanding landscape of proteomics and genomics research, as well as increased research and development efforts in the life sciences domain.

Competitive Landscape

Key antibody fragments market players are focusing on expanding into new markets and developing new products. Key manufacturers' expansion strategy, new product launches and approvals, agreements, partnerships, collaborations, and developed distribution channels such as online sales are strengthening their market presence.

Recent Development

Date	Company Name	Strategy	Details
March 2021	Wuxi Biologics	Agreement	Wuxi Biologics entered into an equity agreement with Pfizer in March 2021 to acquire its biologics drug substance and drug manufacturing facilities in China, as well as the workforce. This acquisition will assist Wuxi in expanding its drug substance and drug product portfolio in the Chinese market.
March 2021	AGC Biologics	Manufacturing Facility	AGC Biologics opened a new manufacturing facility in Italy in March 2021 to expand its manufacturing capacity and implement viral vector suspension capabilities. Such expansions will help the company strengthen its position in the CDMO market.
August 2020	Avid Bioservices	Contract	Avid Bioservices signed a contract with Mapp Biopharmaceutical Inc. in August 2020 for the clinical development of novel human monoclonal antiviral antibodies.
January 2020	Adaptimmune Therapeutics plc	Collaboration	Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, announced a collaboration agreement with Astellas Pharma Inc., a Japanese pharmaceutical company, in January 2020, to develop and commercialise TCR T cell therapies and stem-cell-derived allogeneic chimeric antigen receptor (CAR)-T to treat a large patient population suffering from immunodeficiency caused by various types of cancer, including solid tumours.
May 2020	Centre for Cellular and Molecular Biology	Collaboration	The Centre for Cellular and Molecular Biology and the University of Hyderabad announced collaboration with Vins Bioproducts Ltd. in May 2020 to develop immunotherapy based on antibody fragments for COVID-19 treatment.
March 2021	Amgen Inc.	Acquisitions	Amgen Inc. announced the USD 1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company, and its lead candidate, bemarituzumab, for gastric cancer, in March 2021, in order to broaden the scope of targeted cancer therapies and immuno-oncology.
March 2021	Amgen Inc.	Acquisitions	Amgen Inc. announced the USD 720 million acquisition of Rodeo Therapeutics, a privately held biopharmaceutical company, in March 2021 to develop small-molecule therapies for the regeneration and repair of multiple tissues.

Key Segments  

• By Specificity

  • Monoclonal Antibodies
  • Polyclonal Antibodies

• By Type

  • FAB
  • scFv
  • sdAb
  • Others

• By Therapy

  • Monoclonal Antibodies
  • PAB
  • Pipeline

• By Application

  • Cancer
  • Immunodeficiency
  • Others

• By Region

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe